# Introduction

Roche Diagnostics hereby submits this 510(k) to provide FDA with notification of intent to market the cobas c 501 Tina-quant HbA1cDx Gen.3 assay with a new intended use that includes the device as an aid in the diagnosis of diabetes and as an aid in identifying patients who may be at risk of developing diabetes. This submission presents data to support this new intended use.

# Submitter

Susan Hollandbeck from Roche Diagnostics, U.S. Regulatory Affairs

# Date prepared

The submission was originally prepared on May 31, 2012.

# Device name

Proprietary name: cobas c 501 Tina-quant Hemoglobin A1cDx Gen.3 assay

Common names: HbA1cDx Gen.3 and TQ HbA1cDx Gen.3

Classification name: Hemoglobin A1c Test System

Product codes: PDJ

C.F.R. Section: 862.1373

# Device description

Whole blood samples are placed on the analyzer. The anticoagulated whole blood is hemolyzed on board the analyzer prior to determination of HbA1c by this turbidimetric inhibition immunoassay. Liberated hemoglobin in the hemolyzed sample is converted to a derivative having a characteristic absorption spectrum and measured bichromatically. The instrument first measures hemoglobin (Hb) and glycohemoglobin (HbA1c) in terms of either $\mathbf { g } / \mathrm { d L }$ or mmol/L, then calculates the $\%$ HbA1c from the HbA1c/Hb ratio according to a user-selected protocol, either IFCC or NGSP protocols.

# Predicate device

The cobas c Tina-quant HbA1cDx Gen.3 assay is substantially equivalent to the COBAS INTEGRA 800 Tina-quant HbA1cDx Gen.2 assay that was cleared in 510(k) k121291.

# Intended use

This test is to be used as an aid in diagnosis of diabetes and as an aid in identifying patients who may be at risk for developing diabetes. The cobas c 501Tina-quant HbA1cDx Gen.3 assay is an in vitro diagnostics reagent system intended for quantitative determination of mmol/mol hemoglobin Alc (IFCC) and $\%$ hemoglobin A1c (DCCT/NGSP) in whole blood on the Roche/Hitachi cobas c 501 clinical chemistry analyzer.

The table compares the features of the candidate device, cobas c Tina-quant HbA1cDx Gen.3 assay, to the predicate device, COBAS INTEGRA 800 HbA1cDx Gen.2 that was cleared in 510(k) k121291.

Comparison to predicate   
Comparison Table   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td><td rowspan=1 colspan=1>Anticoagulated venous or capillarybloodAcceptable anticoagulants.Li-Heparin. K2-EDTA. K3-EDTA. KF/Na2-EDTA. Na-Heparin.NaF/K-Oxalate.NaF/Na2-EDTA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Instrument Platform</td><td rowspan=1 colspan=1>cobas e 501</td><td rowspan=1 colspan=1>COBAS INTEGRA 800</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>C.f.a.s. HbAlc</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Frequency</td><td rowspan=1 colspan=1>Each lot, every 29 days, and asrequired following quality controlprocedures</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Mode</td><td rowspan=1 colspan=1>Hb determination uses a linearmode.HbAlc determination uses aspline mode.</td><td rowspan=1 colspan=1>Logit/Log 5</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>PreciControl HbA1c norm and path</td><td rowspan=1 colspan=1>Same</td></tr></table>

Comparison to predicate (continued)

The table compares the features of the candidate device, cobas c Tinaquant HbA1cDx Gen.3 assay, to the predicate device, COBAS INTEGRA 800 HbA1cDx Gen.2 that was cleared in 510(k) k121291.

Comparison Table (continued)   

<table><tr><td>Feature</td><td>Candidate Device</td><td>Predicate Device</td></tr><tr><td rowspan="2">Reporting Units</td><td>For the components, Hb and HbAlc: mmol/L and g/dL</td><td>Components: g/dL</td></tr><tr><td>For the ratio: % HbA1c (DCCT/NGSP) and mmol/mol HbA1c (IFCC)</td><td>Ratio: Same</td></tr><tr><td>Determination of HbAlc</td><td>HbAlc determination is based on the turbidimetric inhibition immunoassay for hemolyzed whole blood. Glycohemoglobin in the sample reacts with anti-HbA1c to form soluble antigen-antibody complexes. Polyhaptens react with excess anti- HbA1c to form an insoluble antibody- polyhapten complex which can be measured turbidimetrically.</td><td>Same</td></tr><tr><td>Determination of Hb</td><td>Liberated hemoglobin in the hemolyzed sample is converted to a derivative having a characteristic absorption spectrum which is measured bichromatically.</td><td>Same</td></tr><tr><td>Sample Pretreatment</td><td>Automated on-board sample pretreatment with hemolyzing reagent Hb</td><td>Same</td></tr><tr><td rowspan="4">Measuring Range</td><td>2.48 - 24.8 mmol/L (4 -40 g/dL)</td><td>Hb 4 - 35 g/dL</td></tr><tr><td>HbA1c 0.186 - 1.61 mmol/L (0.3 - 2.6 g/dL)</td><td>HbA1c 0.3 - 3.4 g/dL</td></tr><tr><td>Ratio 4.2 - 20.1 % HbA1c 23  196 mmol/mol HbA1c</td><td>Ratio 4.3 - 24.8 % HbA1c 23 - 258 mmol/mol HbA1c</td></tr><tr><td>Note: This measuring range was established in 510(k) k102914 for the COBAS INTEGRA Tina-quant HbAlc Gen.3 assay.</td><td></td></tr></table>

The table compares the features of the candidate device, cobas c Tina-quant HbA1cDx Gen.3 assay, to the predicate device, COBAS INTEGRA 800 HbA1cDx Gen.2 that was cleared in 510(k) k121291.

Comparison to predicate (continued)   
Comparison Table (continued)   

<table><tr><td rowspan=1 colspan=3>comparlson l able (contlnueu)</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Polyclonal anti-HbA1c from sheep blood</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent Stability</td><td rowspan=1 colspan=1>Unopened2-8 °C until expiration date on cobas cpack labelOn-board in useRefrigerated on the analyzer for 4 weeks</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analytical Sensitivity</td><td rowspan=1 colspan=1>HbLoB = 0.31 mmol/L (0.50 g/dL)LoD = 0.62 mmol/L (1.00 g/dL)HbA1cLoB = 0.12 mmol/L (0.19 g/dL)LoD = 0.18 mmol/L (0.29 g/dL)</td><td rowspan=1 colspan=1>HbLoB = 0.50 g/dLLoD = 1.00 g/dLHbAlcLoB = 0.19 g/dLLoD = 0.29 g/dL</td></tr><tr><td rowspan=1 colspan=1>Analytical Specificity</td><td rowspan=1 colspan=1>Hb fractionsAt physiological concentrations, no crossreactions were found withHbA0,HbAla,HbA1b,acetylated hemoglobin,carbamylated hemoglobin,glycated albumin, andlabile HbAlc.Hb variantsThis device has significant negativeinterference with samples containingelevated levels of HbF. The bias exceeds-7% when HbF content exceeds +7%. Thenegative bias with HbF is independent of% HbAlc, but is directly proportional inmagnitude to the % HbF content.HbS, HbC, HbD, HbA2, and HbE do notsignificantly interfere.</td><td rowspan=1 colspan=1>Same.Same</td></tr></table>

Comparison to predicate (continued)

The table compares the features of the candidate device, cobas c Tina-quant HbA1cDx Gen.3 assay, to the predicate device, COBAS INTEGRA 800 HbA1cDx Gen.2 that was cleared in 510(k) k121291.

Comparison Table (continued)   

<table><tr><td>Feature</td><td>Candidate Device</td><td>Predicate Device</td></tr><tr><td rowspan="6">Endogenous Interferences</td><td>Icterus No significant interference up to 60 mg/dL.</td><td>Icterus Same</td></tr><tr><td>Lipemia No significant interference up to an</td><td>Lipemia No significant interference up to an</td></tr><tr><td>Intralipid concentration of 600 mg/dL. Glycemia No significant interference up to 1000</td><td>Intralipid concentration of 800 mg/dL. Glycemia Same</td></tr><tr><td>mg/dL. Rheumatoid factors</td><td>Rheumatoid factors</td></tr><tr><td>No significant interference up to 750 IU/mL. Total Protein Up to 21 g/dL of additional protein</td><td>Same Total Protein</td></tr><tr><td>spiked into the sample does not interfere. Drugs</td><td>Same</td></tr><tr><td>No interference was found at common drug panel of 16 drugs. Protocol 1 (IFCC)</td><td>Drugs therapeutic concentrations using a</td><td>Same</td></tr><tr><td rowspan="2">Expected Values</td><td>20 - 42 mmol/mol HbA1c</td><td>Same</td></tr><tr><td>Protocol 2 (DCCT/NGSP) 4.0 - 6.0 % HbA1c</td><td></td></tr></table>

Analytical performance The following discusses the precision of the device.

# Precision

Precision was evaluated according to CLSI EP5-A2. It included evaluation of three reagent lots, three cobas c 501 analyzers, four native samples and two control samples, two aliquots per sample run in singlicate, two runs per day for 21 days. Results are in terms of $\%$ HbAlc.

<table><tr><td rowspan=1 colspan=11>c 501 - Analyzer I Precision</td></tr><tr><td rowspan=3 colspan=1>Mean</td><td rowspan=2 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-</td><td rowspan=1 colspan=2>Between-</td><td rowspan=1 colspan=2>Between-</td><td rowspan=2 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=2>run</td><td rowspan=1 colspan=2>day</td><td rowspan=1 colspan=2>lot</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Human Sample 1(5.0 %HbA1c)</td><td rowspan=1 colspan=1>0.056</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.102</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Human Sample 2(6.4 %HbA1c)</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.095</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.129</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Human Sample 3(7.9 %HbAlc)</td><td rowspan=1 colspan=1>0.078</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.087</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.139</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Human Sample 4(11.3 %HbAlc)</td><td rowspan=1 colspan=1>0.116</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.239</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.278</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>PreciControl HbAIc norm(5.2 %HbAlc)</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.050</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.115</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>PreciControl HbAlc path(9.4 %HbA1c)</td><td rowspan=1 colspan=1>0.085</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.177</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.206</td><td rowspan=1 colspan=1>2.2</td></tr></table>

<table><tr><td rowspan=1 colspan=11>c 501 - Analyzer 2 Precision</td></tr><tr><td rowspan=3 colspan=1>Mean</td><td rowspan=2 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-</td><td rowspan=1 colspan=2>Between-</td><td rowspan=1 colspan=2>Between-</td><td rowspan=2 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=2>run</td><td rowspan=1 colspan=2>day</td><td rowspan=1 colspan=2>lot</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Human Sample 1(5.1 %HbAlc)</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.028</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Human Sample 2(6.4 %HbA1c)</td><td rowspan=1 colspan=1>0.072</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.055</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.043</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.105</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Human Sample 3(8.1 %HbAIc)</td><td rowspan=1 colspan=1>0.081</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.133</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Human Sample 4(11.4 %HbAlc)</td><td rowspan=1 colspan=1>0.107</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.076</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.175</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.232</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>PreciControl HbAIc norm(5.2 %HbAlc)</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.090</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>PreciControl HbA1c path(9.6 %HbA1c)</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.078</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.138</td><td rowspan=1 colspan=1>1.4</td></tr></table>

Analytical performance (continued) The following discusses the precision of the device.

<table><tr><td rowspan=1 colspan=11>Precision results are in terms of % HbA1c.</td></tr><tr><td rowspan=1 colspan=11>c501 - Analyzer 3 Precision</td></tr><tr><td rowspan=3 colspan=1>Mean</td><td rowspan=2 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-</td><td rowspan=1 colspan=2>Between-</td><td rowspan=1 colspan=2>Between-</td><td rowspan=2 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=2>run</td><td rowspan=1 colspan=2>day</td><td rowspan=1 colspan=2>lot</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Human Sample 1(5.0 %HbA1c)</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.020</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.103</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Human Sample 2(6.4 %HbA1c)</td><td rowspan=1 colspan=1>0.076</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.037</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.094</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Human Sample 3(8.0 %HbA1c)</td><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.055</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.073</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.138</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Human Sample 4(11.3 %HbAlc)</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.036</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.157</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>PreciControl HbAlc norm(5.2 %HbAlc)</td><td rowspan=1 colspan=1>0.076</td><td rowspan=1 colspan=1>&#x27;1.5</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.133</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.156</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>PreciControl HbAlc path(9.5 %HbAlc)</td><td rowspan=1 colspan=1>0.121</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.116</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.174</td><td rowspan=1 colspan=1>1.8</td></tr></table>

<table><tr><td rowspan=1 colspan=13>Reproducibility — Roche/Hitachi cobas c 501</td></tr><tr><td rowspan=3 colspan=1>Mean</td><td rowspan=2 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-</td><td rowspan=1 colspan=2>Between-</td><td rowspan=1 colspan=2>Between-</td><td rowspan=2 colspan=2>Between-instrument</td><td rowspan=2 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=2>run</td><td rowspan=1 colspan=2>day</td><td rowspan=1 colspan=2>lot</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Human Sample 1(5.1 %HbAlc)</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.036</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Human Sample 2(6.4 %HbA1c)</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Human Sample 3(8.0 %HbAIC)</td><td rowspan=1 colspan=1>0.087</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.056</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.071</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.169</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>Human Sample 4(11.3 %HbA1c)</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.172</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.227</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>PreciControlHbAlc norm(5.2 %HbAIc)</td><td rowspan=1 colspan=1>0.068</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.090</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.123</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>PreciControlHbAlc path(9.5 %HbA1c)</td><td rowspan=1 colspan=1>0.102</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.130</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.079</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.192</td><td rowspan=1 colspan=1>2.0</td></tr></table>

Analytical performance (continued)

The following discusses the method comparison and total error.

# Method Comparison

A method comparison was performed to compare sample results from the candidate method using one reagent lot on one cobas c 501 analyzer to sample results from Tosoh HPLC, the secondary NGSP reference laboratory method. Samples were tested in singlicate and measured over three days. 141 variant-free samples ranged from 4.7 to $1 2 . 2 \%$ HbA1c. The distribution of samples tested appears below.

Sample Distribution   

<table><tr><td rowspan=1 colspan=1>% HbA1c</td><td rowspan=1 colspan=1># sample tested</td><td rowspan=1 colspan=1>% samples tested</td></tr><tr><td rowspan=1 colspan=1>&lt;5%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>5-6%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>14.9%</td></tr><tr><td rowspan=1 colspan=1>6-6.5%</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>19.9%</td></tr><tr><td rowspan=1 colspan=1>6.5-7%</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>23.4%</td></tr><tr><td rowspan=1 colspan=1>7-8%</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>19.1%</td></tr><tr><td rowspan=1 colspan=1>8-9%</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>10.6%</td></tr><tr><td rowspan=1 colspan=1>&gt; 9%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>8.5%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>141</td><td rowspan=1 colspan=1>100%</td></tr></table>

Total Error The bias component from the method comparison study and the precision component from the reproducibility study are used to calculate the total error at three concentrations near the cutoff.

Total Error   

<table><tr><td rowspan=1 colspan=1>Decision Level (% HbA1c)</td><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>-1.98%</td><td rowspan=1 colspan=1>2.07%</td><td rowspan=1 colspan=1>6.0%</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>-1.45%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>4.7%</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>-1.06%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>5.1%</td></tr></table>

Analytical performance (continued)

The following discusses the endogenous interference.

# Endogenous Interference

Six endogenous substances were evaluated for potential interference of the assay. These substances were spiked into whole blood sample pools. A separate preparation occurred for each substance. Two HbAlc levels, one near the medical decision level and one above it, were tested for each endogenous substance. Thus twelve dilution series were created.

Each sample in each dilution series was tested ten-fold for $\%$ HbA1c on a single cobas c 501 analyzer, using a single reagent lot.

The median value for each set of ten was calculated. The reference sample is the sample Level 0 in the dilution series; it contains no interferent.The initial value is the measured result for the reference sample. The results for all remaining samples in the dilution series are compared to the initial value. This comparison is evaluated as a percent deviation. Interference is significant when it exceeds $7 \%$ deviation from the initial value.

Endogenous Interference Summary   

<table><tr><td rowspan=1 colspan=1>endogenous substance</td><td rowspan=1 colspan=1>range tested</td><td rowspan=1 colspan=1>highest level tested withno significant interference</td></tr><tr><td rowspan=1 colspan=1>Lipemia (Intralipid)</td><td rowspan=1 colspan=1>0-2000 mg/dL</td><td rowspan=1 colspan=1>600 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin</td><td rowspan=1 colspan=1>0-66 mg/dL</td><td rowspan=1 colspan=1>60mg/dL</td></tr><tr><td rowspan=1 colspan=1>Conjugated Bilirubin</td><td rowspan=1 colspan=1>0-66 mg/dL</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>0-2000mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>0-1200 IU/mL</td><td rowspan=1 colspan=1>750 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Total Protein</td><td rowspan=1 colspan=1>0-24.5 g/dL</td><td rowspan=1 colspan=1>21 g/dL</td></tr></table>

Analytical performance The following discusses the drug interference. (continued)

# Drug Interference

Sixteen drugs were evaluated for potential interference of the assay. These drugs were spiked into whole blood samples at two concentrations, Concentration 1 is ${ \sim } 5$ times the maximum daily dose and Concentration 2 is the maximum daily dose. A separate preparation occurred for each drug. Two HbAlc levels, one near the medical decision level and one above it, were tested for each drug. Thus, 64 samples were prepared. Also, an HbAlc sample with no drug served at the reference sample.

Each sample was tested ten-fold for $\%$ HbAIc on a single cobas c 501 analyzer, using a single reagent lot.

The median value for each set of ten was calculated and compared to the initial value. Percent recovery was calculated. Interference is significant when it exceeds $7 \%$ deviation from the initial value. Results show that no significant interference was observed with the following drugs up to the stated concentrations.

Drug Interference Summary   

<table><tr><td rowspan=1 colspan=1>drug</td><td rowspan=1 colspan=1>highest level tested with no significant interference</td></tr><tr><td rowspan=1 colspan=1>Acetylcystein</td><td rowspan=1 colspan=1>150 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ampicillin-Na</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>300 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>2500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>5000 U/L</td></tr><tr><td rowspan=1 colspan=1>Levodopa</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Methyldopa</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>200 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Doxycyclin</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>60 mg/L</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine</td><td rowspan=1 colspan=1>5 mg/L</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>200 mg/L</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>500 mg/L</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>100 mg/L</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>400 mg/L</td></tr></table>

Analytical performance (continued)

The following discusses cross-reactivity with hemoglobin derivatives.

# Cross-Reactivity with Hemoglobin Derivatives

Six hemoglobin derivatives were evaluated for potential interference of the assay. Two HbAlc levels, one near the medical decision level and one above it, were represented in whole blood sample pools. For each HbA1c level, two whole blood pools were prepared for each derivative, one with none and one with a high concentration of derivative. From the pools, a serial dilution was prepared to yield varying concentrations of the derivative for both HbAlc levels.

Each sample was tested ten-fold for $\%$ HbA1c on a single cobas c 501 analyzer, using a single reagent lot.

The median value for each set of ten was calculated. The reference sample is the sample Level 0 in the dilution series; it contains no interferent. The initial value is the measured result for the reference sample. The results for all remaining samples in the dilution series are compared to the initial value. This comparison is evaluated as a percent deviation. Interference is significant when it exceeds $7 \%$ deviation from the initial value.

Cross-Reactivity with Hemoglobin Derivatives Summary   

<table><tr><td rowspan=1 colspan=1>endogenous substance</td><td rowspan=1 colspan=1>range tested</td><td rowspan=1 colspan=1>bighest level tested withno significant interference</td></tr><tr><td rowspan=1 colspan=1>HbA0</td><td rowspan=1 colspan=1>0-120 g/dL</td><td rowspan=1 colspan=1>120 g/dL</td></tr><tr><td rowspan=1 colspan=1>HbAla+b</td><td rowspan=1 colspan=1>0-0.64 g/dL</td><td rowspan=1 colspan=1>0.48 g/dL</td></tr><tr><td rowspan=1 colspan=1>Acetylated Hb</td><td rowspan=1 colspan=1>0-2.0 g/dL</td><td rowspan=1 colspan=1>2.0g/dL</td></tr><tr><td rowspan=1 colspan=1>Carbamylated Hb</td><td rowspan=1 colspan=1>0-1.0 g/dL</td><td rowspan=1 colspan=1>1.0 g/dL</td></tr><tr><td rowspan=1 colspan=1>Labile HbAlc</td><td rowspan=1 colspan=1>0-100 mg/dL</td><td rowspan=1 colspan=1>100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Glycated Albumin</td><td rowspan=1 colspan=1>0-10 g/dL</td><td rowspan=1 colspan=1>10 g/dL</td></tr></table>

Tv ysy occurring concentrations.

Analytical performance The following discusses the interference with hemoglobin varants.

# Hemoglobin Variants Interference

A hemoglobin variant interference study was performed using a total of 116 samples that contain one of six common hemoglobin variants. This table summarizes the sample profile.

Representation of Hemoglobin Variants   

<table><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>Quantityof Samples</td><td rowspan=1 colspan=1>Range of% Content of Variant</td><td rowspan=1 colspan=1>Range ofConcentration in % HbAlc</td></tr><tr><td rowspan=1 colspan=1>S</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>31 - 42% S</td><td rowspan=1 colspan=1>4.60 - 13.0</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>33 - 44% C</td><td rowspan=1 colspan=1>4.68  13.0</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>27 - 33% E</td><td rowspan=1 colspan=1>5.00 - 9.68</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>34 - 42% D</td><td rowspan=1 colspan=1>4.79-9.78</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>2-28% F</td><td rowspan=1 colspan=1>5.83 - 10.1</td></tr><tr><td rowspan=1 colspan=1>A2</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>4 - 7% A2</td><td rowspan=1 colspan=1>4.90 - 8.56</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=2></td></tr></table>

Testing was performed on the candidate device and with an NGSP reference method that is known to be free from the hemoglobin interference being tested. This table categorizes results for the variants as they are impacted by $\%$ HbA1c concentration. The results reflect bias between actual sample results. Interference $> 7 \%$ deviation from the reference method is significant.

Hemoglobin Variant Study Results Summary   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Percent Relative Bias from Reference Methodat Low and High Concentrations of HbA1c Samples</td></tr><tr><td rowspan=1 colspan=1>Hb Variant</td><td rowspan=1 colspan=1>6.0 % HbA1c</td><td rowspan=1 colspan=1>9.0 % HbAlc</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>-3.07</td><td rowspan=1 colspan=1>-0.35</td></tr><tr><td rowspan=1 colspan=1>S</td><td rowspan=1 colspan=1>2.17</td><td rowspan=1 colspan=1>3.42</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>-1.58</td><td rowspan=1 colspan=1>3.46</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>-2.30</td><td rowspan=1 colspan=1>3.35</td></tr><tr><td rowspan=1 colspan=1>A2</td><td rowspan=1 colspan=1>-5.73</td><td rowspan=1 colspan=1>-4.12</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=2>Bias exceeds -7%when HbF content exceeds + 7%.1</td></tr></table>

'A negative bias with HbF is independent of $\%$ HbA1c but is directly proportional in magnitude to the $\%$ HbF content.

Analytical performance The following discusses the lower limits of detection and linearity. (continued)

# Lower Limits of Detection

LoB (Limit of Blank) and LoD (Limit of Detection) were determined according to CLSI EP17-A.

LoB was determined using one analyte-free sample tested in five replicates on two cobas c 501 analyzers. LoD was determined using five low-analyte samples tested in singlicate on two cobas c 501 analyzers. Both LoB and LoD were evaluated for Hb and HbA 1c (g/dL). The tests were performed in two runs per day for three days per reagent batch with a total of three reagent batches.

LoB and LoD   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Hb (g/dL)</td><td rowspan=1 colspan=2>HbA1c (g/dL)</td></tr><tr><td rowspan=1 colspan=1>Reagent Batch</td><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.0380</td><td rowspan=1 colspan=1>0.0948</td><td rowspan=1 colspan=1>0.0097</td><td rowspan=1 colspan=1>0.0239</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.0210</td><td rowspan=1 colspan=1>0.0594</td><td rowspan=1 colspan=1>0.0079</td><td rowspan=1 colspan=1>0.0197</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.0445</td><td rowspan=1 colspan=1>0.1133</td><td rowspan=1 colspan=1>0.0163</td><td rowspan=1 colspan=1>0.0315</td></tr></table>

# Linearity

Linearity was performed according to CLSl EP6-A for this submission and for 510(k) k102914. For this submission, a dilution series was prepared using a high analyte concentration sample pool and an analyte-free pool. The pools were mixed in different ratios to yield a 20-level dilution series with varying concentrations of Hb and HbA1c. Values were measured in triplicate for each level. The median values were compared to the theoretical values and regressed.

The linearity results from this study and from the one included in 510(k) k102914 support the claimed reportable range.

Linearity Summary   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Unit of Measure</td><td rowspan=1 colspan=1>Linear Range</td></tr><tr><td rowspan=2 colspan=1>Glycohemoglobin</td><td rowspan=1 colspan=1>mmol/L HbAlc</td><td rowspan=1 colspan=1>0.186-1.61</td></tr><tr><td rowspan=1 colspan=1>g/dL HbA1c</td><td rowspan=1 colspan=1>0.30-02.6</td></tr><tr><td rowspan=2 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>mmol/L Hb</td><td rowspan=1 colspan=1>2.48  24.8</td></tr><tr><td rowspan=1 colspan=1>g/dL Hb</td><td rowspan=1 colspan=1>4-40</td></tr><tr><td rowspan=2 colspan=1>Ratio</td><td rowspan=1 colspan=1>% HbA1c (DCCT/NGSP)</td><td rowspan=1 colspan=1>4.2- 20.1</td></tr><tr><td rowspan=1 colspan=1>mmol/mol HbA1c (IFCC)</td><td rowspan=1 colspan=1>23-196</td></tr></table>

# August 8, 2013

Roche Diagnostics   
c/o Ms. Susan Hollandbeck   
Regulatory Affairs Consultant   
9115 Hague Road   
INDIANAPOLIS IN 46256

Re: k121610 Trade/Device Name: cobas c 501 Tina-quant HbA1cDx Gen.3 Assay Regulation Number: 21 CFR $\ S 8 6 2 . 1 3 7 3$ EY Regulation Name: Hemoglobin Alc Test System Regulatory Class: Class II Product Code: PDJ Dated: July 26, 2013 Received: July 29, 2013

Dear Ms. Hollandbeck:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Intemet address   
http://www.fda.gov/cdrh/industry/support/index.htnl.

Sincerely yours,

Carol C. Benson -S for

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices   
Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number (if known): k121610

Device Name:

cobas c 501 Tina-quant HbA1cDx Gen.3

Indications for Use:

This test is to be used as an aid in diagnosis of diabetes and as an aid in identifying patients who may be at risk for developing diabetes. The cobas c 501 Tina-quant HbA1cDx Gen.3 assay is an in vitro diagnostics reagent system intended for quantitative determination of mmol/mol hemoglobin A1c (IFCC) and $\%$ hemoglobin Alc (DCCT/NGSP) in whole blood on the Roche/Hitachi cobas c 501 clinical chemistry analyzer.

Prescription Use X (21 CFR Part 801 Subpart D)

And/Or

Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

Division Sign-Off